Drug Profile
Research programme: hypertension therapy - Lexicon Pharmaceuticals/Takeda
Alternative Names: Hypertension therapy research programme - Lexicon Pharmaceuticals/Takeda; LG 105; LG 844; LG-474Latest Information Update: 13 Feb 2014
Price :
$50
*
At a glance
- Originator Lexicon Genetics; Takeda
- Developer Lexicon Pharmaceuticals; Takeda
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 13 Jan 2014 Discontinued - Preclinical for Hypertension in USA (unspecified route)
- 27 Nov 2008 This programme is still in active development
- 27 Apr 2007 Lexicon Genetics is now called Lexicon Pharmaceuticals